BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34893342)

  • 1. Reactivity characterization of bromoacetyl derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB® by NMR spectroscopy.
    Rustandi RR; Xu Q
    Vaccine; 2022 Jan; 40(2):187-191. PubMed ID: 34893342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring bromide loss in bromoacetyl-derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB® by capillary electrophoresis and NMR spectroscopy.
    Rustandi RR; Hamm M; Onimus M; Yuan Y; Anderson CL; Zong C
    Vaccine; 2022 Oct; 40(42):6012-6016. PubMed ID: 36123258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data.
    Heath PT
    Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S117-22. PubMed ID: 9781743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative nuclear magnetic resonance analysis and characterization of the derivatized Haemophilus influenzae type b polysaccharide intermediate for PedvaxHIB.
    Xu Q; Klees J; Teyral J; Capen R; Huang M; Sturgess AW; Hennessey JP; Washabaugh M; Sitrin R; Abeygunawardana C
    Anal Biochem; 2005 Feb; 337(2):235-45. PubMed ID: 15691503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An enzyme-linked immunosorbent assay for quantitation of Haemophilus Influenzae type b polysaccharide-specific IgG1 and IgG2 in human and infant rhesus monkey sera.
    Dolan KT; Staub JM; Schofield TL; Ahonkhai VI; Ellis RW; Vella PP
    J Immunoassay; 1991; 12(4):543-64. PubMed ID: 1806588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of naturally acquired and vaccine-induced antibodies to Haemophilus influenzae type b capsular polysaccharide.
    Jelonek MT; Chang SJ; Chiu CY; Park MK; Nahm MH; Ward JI
    Infect Immun; 1993 Dec; 61(12):5345-50. PubMed ID: 8225608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children.
    Harrison LH; Tajkowski C; Croll J; Reid R; Hu D; Brenneman G; Weatherholtz RC; Santosham M
    J Pediatr; 1994 Oct; 125(4):571-6. PubMed ID: 7931875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease caused by Haemophilus influenzae type b in the immediate period after homologous immunization: immunologic investigation.
    Sood SK; Daum RS
    Pediatrics; 1990 Apr; 85(4 Pt 2):698-704. PubMed ID: 2107522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
    Gray BM
    Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemophilus influenzae type b capsular polysaccharide antibody levels in Japanese young patients with hematological malignancies and asplenia.
    Takeshita K; Ishiwada N; Takeuchi N; Takahashi Y; Fukasawa C; Hishiki H; Hoshino T; Shimojo N
    J Infect Chemother; 2020 Sep; 26(9):959-962. PubMed ID: 32402734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reemergence of invasive Haemophilus influenzae type b disease in Alaska: Is it because of vaccination with polyribosylribitol phosphate outer membrane protein complex (PRP-OMPC) or failure to vaccinate with PRP-OMPC?
    Dargan JM; Coplan PM; Kaplan KM; Nikas A
    J Infect Dis; 2000 Feb; 181(2):806-9. PubMed ID: 10669389
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine (PedvaxHIB) in Papua New Guinean children.
    Lehmann D; Kakazo M; Yarsley S; Javati A; Taime J; Saleu G; Namuigi P; Alpers MP; Mendelman PM; Staub T
    P N G Med J; 1998; 41(3-4):102-11. PubMed ID: 10934551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Haemophilus influenzae type b disease.
    Santosham M
    Vaccine; 1993; 11 Suppl 1():S52-7. PubMed ID: 8447177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine.
    Donnelly JJ; Deck RR; Liu MA
    J Immunol; 1990 Nov; 145(9):3071-9. PubMed ID: 2120344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
    Schlesinger Y; Granoff DM
    JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide.
    Sturgess AW; Rush K; Charbonneau RJ; Lee JI; West DJ; Sitrin RD; Hennessy JP
    Vaccine; 1999 Mar; 17(9-10):1169-78. PubMed ID: 10195629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.